Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that ...

Edwards Lifesciences announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic ...

It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

With standardized workflows, the Control System is engineered to improve TAVR temporary pacing efficiency and reduce patient risks. Initial cases were completed this month at Scripps Clinic by Chief ...

Unlike traditional open-heart surgery, TAVR is a less invasive way to replace a narrowed ... scale brush removal campaign and asking residents to help reduce wildfire risks as temperatures rise. 5 ...